Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 67

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 67
---
30 per share, assuming all of our common stock in the aggregate amount of $200.0 million is sold at that price, would result in an adjusted net tangible book value per share after the offering of $1.48 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $1.82 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only.

The above discussion and table are based on 180,309,471 shares of our common stock outstanding as of September 30, 2025 excludes:

• 16,393,177 shares of common stock issuable upon the exercise of stock options outstanding as of September 30, 2025, at a weighted average exercise price of $3.78 per share;

<div align='center'>S-8</div>

• 8,655,858 shares of common stock available for future issuance under our 2022 Stock Option and Incentive Plan as of September 30, 2025, as well as any increases in the number of shares of common stock reserved for issuance thereunder; and

• 1,619,579 shares of common stock available for future issuance under our 2022 Employee Stock Purchase Plan as of September 30, 2025, as well as any increases in the number of shares of common stock reserved for issuance thereunder.

Unless otherwise stated, all information contained in this prospectus assumes no exercise of stock options, vesting of restricted common stock, or issuances of shares under the 2022 Employee Stock Purchase Plan after September 30, 2025 and reflects an assumed public offering price of $4.30, which was the last reported sale price of our common stock on The Nasdaq Global Market on November 4, 2025.

To the extent that outstanding stock options are exercised, shares of common stock are issued upon the vesting of outstanding restricted common stock or under our 2022 Employee Stock Purchase Plan, new options are issued under our 2022 Stock Option and Incentive Plan, or we otherwise issue additional shares of common stock in the future at a price less than the assumed public offering price, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through